Crossmark

Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity

Crossref DOI link: https://doi.org/10.1136/jitc-2023-007960

Published Online: 2024-01-31

Published Print: 2024-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Wright, Quentin G https://orcid.org/0000-0001-9628-0200
Sinha, Debottam https://orcid.org/0000-0001-7153-856X
Wells, James W https://orcid.org/0000-0002-9618-6940
Frazer, Ian H

Gonzalez Cruz, Jazmina L https://orcid.org/0000-0003-2671-7408
Leggatt, Graham Robert https://orcid.org/0000-0002-4078-5653
Funding

Funding for this research was provided by:

Tour de Cure (RSP-206-2020)

Australian Government Research Training Program Scholarship (N/A)
License Information

License valid from 2024-01-31